SK biopharmaceuticals Co., Ltd.
Develops and commercializes treatments for central nervous system disorders and oncology.
326030 | KO
Overview
Corporate Details
- ISIN(s):
- KR7326030004
- LEI:
- Country:
- South Korea
- Address:
- 경기도 성남시 분당구 판교역로 221, 성남시
- Website:
- https://www.skbp.com/
- Sector:
- Manufacturing
Description
SK biopharmaceuticals is a pharmaceutical company focused on the research, development, and commercialization of innovative treatments, primarily for central nervous system (CNS) disorders. The company's portfolio is led by Cenobamate, an anti-seizure medication for epilepsy that was discovered and developed in-house, and also includes the commercialized product Solriamfetol. Its development pipeline features candidates such as Carisbamate. Strategically, the company is expanding into new therapeutic areas, notably oncology through the development of a Radiopharmaceutical Therapy (RPT) portfolio, and is advancing digital healthcare solutions, including an AI-driven platform for epilepsy management. The company operates as a fully integrated global entity, managing the entire value chain from drug discovery to commercialization.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-11-14 00:00 |
동일인등출자계열회사와의상품ㆍ용역거래변경
|
Korean | 10.6 KB | ||
| 2022-11-10 00:00 |
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.7 KB | ||
| 2022-11-07 00:00 |
기업설명회(IR)개최(안내공시)
|
Korean | 6.0 KB | ||
| 2022-10-24 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 8.1 KB | ||
| 2022-09-26 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 8.1 KB | ||
| 2022-08-30 00:00 |
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 8.8 KB | ||
| 2022-08-16 00:00 |
반기보고서 (2022.06)
|
Korean | 2.1 MB | ||
| 2022-08-11 00:00 |
연결재무제표기준영업(잠정)실적(공정공시)
|
Korean | 15.7 KB | ||
| 2022-08-11 00:00 |
동일인등출자계열회사와의상품ㆍ용역거래변경
|
Korean | 9.8 KB | ||
| 2022-08-08 00:00 |
기업설명회(IR)개최(안내공시)
|
Korean | 6.0 KB | ||
| 2022-07-25 00:00 |
단일판매ㆍ공급계약체결
|
Korean | 8.2 KB | ||
| 2022-07-14 00:00 |
투자판단관련주요경영사항(뇌전증 신약 세노바메이트의 라틴아메리카 지역 상업화 권리 이전)
|
Korean | 8.8 KB | ||
| 2022-07-14 00:00 |
동일인등출자계열회사와의상품ㆍ용역거래
|
Korean | 10.6 KB | ||
| 2022-07-13 00:00 |
지속가능경영보고서등관련사항(자율공시)
|
Korean | 7.3 KB | ||
| 2022-05-31 00:00 |
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 136.8 KB |
Automate Your Workflow. Get a real-time feed of all SK biopharmaceuticals Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for SK biopharmaceuticals Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SK biopharmaceuticals Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
